|
 Participants in the Diabetes Control and Complications Trial (DCCT)
who strictly controlled blood sugar after being diagnosed with type
1 diabetes had over 30 percent lower rates of heart disease, heart
attacks and strokes over the next three decades compared to those
who got standard care in those early years.
“Efforts to make intensive diabetes management attainable at a young
age must continue so as to reduce the rates of life-threatening
cardiovascular disease over the life span for patients with
diabetes,” the study authors conclude in the journal Diabetes Care.
Starting with good blood sugar control after being diagnosed with
type 1 diabetes helps to reduce the likelihood of diabetic
complications like blindness and kidney disease.
The DCCT ran from 1983 to 1993, and involved 1,441 volunteers with
type 1 diabetes, ages 13 to 39 years old, as well as 29 medical
centers in the United States and Canada.
Past studies have shown that in the first 10 years, early intensive
diabetes therapy significantly reduced the risk of developing
cardiovascular disease (heart attack, stroke, cardiovascular death,
angina and the need for coronary artery disease treatment).
Now, Dr. Rose Gubitosi-Klug from Case-Western Reserve University in
Cleveland, Ohio, and colleagues report the results over two decades
after the trial concluded, when more than 1,300 patients no longer
had their blood sugar management dictated by the study protocol.
While blood sugar levels were better for the intensive therapy group
during the study, there were only trivial differences in blood sugar
control in the ensuing years between those who originally had
intensive diabetes therapy and those who had the standard diabetes
therapy of the time.
Yet, after an average of 26 years, the risk of having any
cardiovascular event was 30 percent lower in the patients who
originally received intensive diabetes therapy, despite this lack of
difference in blood sugar control in the later years.
The risk of a first nonfatal heart attack, stroke or cardiovascular
death was 32 percent lower with intensive, versus conventional,
therapy.
Blood sugar control in the later years mattered, too – each 10
percent improvement in control (measured by hemoglobin A1C) was
associated with a 17 percent reduction in the risk of a
cardiovascular event.
Gubitosi-Klug did not respond to a request for comments.
[to top of second column] |
Dr. John B. Buse, a diabetes expert from University of North
Carolina School of Medicine in Chapel Hill, told Reuters Health,
“Though we were hopeful that intensive management of diabetes would
be associated with sustained benefits, I do not think anyone
believed that the benefits would be sustained over 30 years of
follow-up in the DCCT. It suggests that there is great value to
improved glycemic control for whatever period of time that it can be
sustained.”
Even so, he said by email, “The one remaining but unanswerable
question is: Does this comparison of intensive management in the
1980’s and 1990’s, as compared to what today would be viewed as
totally inadequate care, really predict the benefit of improved
control though best practices in 2016 as compared to less good
practices today?”
Buse thinks it’s “best to assume that the answer is ‘yes’ and that
targeting near normal blood glucose levels and accepting an A1C of
~7 percent should be the aim of diabetes care today.”
Dr. Rozalina G. McCoy, another proponent of intensive diabetes
therapy from Mayo Clinic in Rochester, Minnesota, said, “For me, as
a practicing primary care physician and endocrinologist, this study
reinforces the importance of starting patients with type 1 diabetes
on treatment early and utilizing every possible resource to help
patients and their families manage their diabetes in a way that not
only achieves and maintains glycemic targets, but is also
sustainable by being affordable and tolerable (e.g., with least
possible hypoglycemia and burden of treatment).”
The study results “will help me engage patients and families in
informed and shared decision-making by showing them that there truly
is benefit to reducing hemoglobin A1C,” she told Reuters Health in
an email.
SOURCE: http://bit.ly/1KOfh1B Diabetes Care, online February 9,
2016.
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
